Get the Stockscreener App
130.05
0.03%
0.02
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $130.05, with a volume of 3.21M.
It is up +0.03% in the last 24 hours and up +1.19% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$130.03
Open:
$130.74
24h Volume:
3.21M
Relative Volume:
0.58
Market Cap:
$200.11B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
16.31
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
+2.42%
1M Performance:
+1.19%
6M Performance:
-3.51%
1Y Performance:
+10.83%
1-Day Range:
$129.29
$132.03
1-Week Range:
$126.55
$132.03
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.06 | 226.11B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
359.06 | 137.72B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.56 | 123.49B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
BSX
Boston Scientific Corp
|
99.80 | 150.85B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
GEHC
Ge Healthcare Technologies Inc
|
71.05 | 32.17B | 20.25B | 2.29B | 1.40B | 4.8366 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
AbbVie Stock Falls 4% -- What Investors Need to Know - The Motley Fool
Sentiment analysis tools applied to Abbott LaboratoriesJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Assessing Abbott Laboratories (ABT) Valuation Potential After Recent Share Price Momentum - simplywall.st
Will earnings trigger a reversal in Abbott LaboratoriesWatch List & Weekly Breakout Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock benefit from infrastructure billQuarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Abbott Laboratories Stock: The Battle for the $140 Threshold - AD HOC NEWS
Can Abbott Laboratories stock surprise with earnings upsideBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report? - Yahoo Finance
What Does the Market Think About Abbott Laboratories? - Benzinga
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Is Abbott Laboratories stock a buy on dipsMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
New data backs Abbott Aveir dual-chamber leadless pacemaker system - MassDevice
Is Abbott Laboratories (Common Stock) (ABL0) stock a top dividend aristocrat candidateQuarterly Earnings Report & Free Fast Gain Swing Trade Alerts - newser.com
Here’s Why Abbott Laboratories (ABT) Traded Down in Q3 - Insider Monkey
Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
FDA expands urgent baby formula recall to all products made by one manufacturer - TheStreet
Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling - Insider Monkey
Abbott competitor's baby formula recalled after infant botulism outbreak - Crain's Chicago Business
Why pension funds invest in Abbott Laboratories (ABL) stockPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Unnatural Amino Acids Market to Reach US$ 5.03 Billion By 2032 Driven by Advances in Drug Discovery, Biologics and Protein Engineering - GlobeNewswire Inc.
A Look at Abbott Laboratories’s Valuation Following Revenue Growth and Maintained Outlook - Yahoo Finance
How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares - Yahoo Finance
Why Abbott Laboratories (ABL) stock could be next leaderQuarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Will a bounce in Abbott Laboratories offer an exit2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Will Recent Share Buybacks Reshape Abbott’s (ABT) Capital Allocation Story? - simplywall.st
Christine Poole's Top Picks: Abbott Labs, CN Rail & Otis Worldwide - BNN Bloomberg
Abbott Laboratories (ABT): Exploring Valuation After Mixed Q3 Earnings and Bullish Analyst Sentiment - simplywall.st
How Abbott Laboratories stock trades during market volatilityJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock maintain strong growthJuly 2025 Setups & Weekly High Return Forecasts - newser.com
U.S. Functional Protein Market to Get an Explosive Growth| - openPR.com
Is a relief rally coming for Abbott Laboratories holdersWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Will Abbott Laboratories stock benefit from infrastructure spendingQuarterly Investment Review & Expert Approved Momentum Trade Ideas - fcp.pa.gov.br
Why Abbott Laboratories (Common Stock) (ABL0) stock is a must watch tickerMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Has Abbott Stock’s Valuation Shifted With Expanded FDA Approvals in 2025? - Yahoo Finance
Why Abbott Laboratories (ABL) stock could outperform next yearQuarterly Trade Report & Expert Curated Trade Ideas - fcp.pa.gov.br
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott Laboratories $ABT Stock Holdings Boosted by Dillon & Associates Inc. - MarketBeat
Tufton Capital Management Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Huntington National Bank Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Commonwealth Retirement Investments LLC Acquires Shares of 20,274 Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem - simplywall.st
Jacobson & Schmitt Advisors LLC Acquires Shares of 2,827 Abbott Laboratories $ABT - MarketBeat
Asia-Pacific Organic Baby Food Market Size and Share Analysis Report (2025-2033) Featuring Profiles of Key PlayersAbbott Labs, Nestle, Danone, Kewpie, and Hero Group Among Others - Yahoo Finance
Bank of New York Mellon Corp Cuts Position in Abbott Laboratories $ABT - MarketBeat
With 80% ownership, Abbott Laboratories (NYSE:ABT) boasts of strong institutional backing - Yahoo Finance
Freestone Capital Holdings LLC Cuts Holdings in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories showing signs of accumulation2025 Valuation Update & Precise Buy Zone Identification - newser.com
Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & SuppliesDiversified Stocks - Barchart.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):